Teicoplanin

Generic Name: Teicoplanin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₈₈H_₉₇Cl_₂N_₉O_₃₃

CAS Number: 61036-62-2

Unique Ingredient Identifier: 4U3D3YY81M

Background: Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine moiety.

Indication: For the treatment of bacterial infections caused by susceptible microorganisms.

Associated Conditions: Angina Pectoris, Anginal Pain, Bacteremia, Bloodstream Infections (BSI), Bone and Joint Infections, Clostridium Difficile, Clostridium Difficile Infection (CDI), Community Acquired Pneumonia (CAP), Complicated Urinary Tract Infection, Infective Endocarditis (IE), Lower Respiratory Tract and Lung Infections, Non-complicated Skin and Soft Tissue Infections, Nosocomial Pneumonia, Peritonitis, Skin and Soft Tissue Infections (SSTIs), Urinary Tract Infection

Associated Therapies: -

Clinical Trials

TDM-optimized Teicoplanin Dosing Versus Standard of Care

Phase 4

Recruiting

Conditions: Bacterial Infections

Interventions: Drug: Teicoplanin

First Posted Date: 2023-06-22

Last Posted Date: 2024-04-16

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 74

Registration Number: NCT05914467

Locations: 🇳🇱
RadboudUMC, Nijmegen, Netherlands

Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy

Phase 4

Completed

Conditions: Cholangitis, Secondary Biliary
Treatment Compliance
Antibodies Drug Specific

Interventions: Drug: Sulperazon
Drug: Meropenem Injection
Drug: Teicoplanin

First Posted Date: 2020-04-30

Last Posted Date: 2022-04-11

Lead Sponsor: Tongji Hospital

Target Recruit Count: 160

Registration Number: NCT04370145

Locations: 🇨🇳
Tongji hospital affiliated to tongji medical college of huazhong university of science and technology, Wuhan, Hubei, China
🇨🇳
TongjiHospital, Wuhan, Hubei, China

Does Teicoplanin Powder Use In Lumbar Instrumentation Surgery Reduce Surgical Site Infection

Phase 3

Conditions: Scoliosis Lumbar Region
Lumbar Disc Lesion
Lumbar Spondylolisthesis
Lumbar Spinal Stenosis
Lumbar Disc Herniation

Interventions: Drug: Teicoplanin

First Posted Date: 2020-04-10

Last Posted Date: 2020-04-14

Lead Sponsor: Bezmialem Vakif University

Target Recruit Count: 120

Registration Number: NCT04341831

Efficacy and Safety of Teicoplanin in CDAD

Phase 4

Terminated

Conditions: Clostridium Difficile Infection-associated Diarrhea and Colitis

Interventions: Drug: TEICOPLANIN

First Posted Date: 2019-07-01

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 50

Registration Number: NCT04003818

Locations: 🇨🇳
investigational site CHINA, China, China

The Amputation Surgical Site Infection Trial (ASSIT)

Phase 4

Completed

Conditions: Wound Infection
Amputation Wound

Interventions: Drug: Co-amoxiclav
Drug: Iodine
Drug: Metronidazole
Drug: Chlorhexidine
Drug: Clindamycin
Drug: Teicoplanin

First Posted Date: 2013-12-23

Last Posted Date: 2019-07-15

Lead Sponsor: Hull University Teaching Hospitals NHS Trust

Target Recruit Count: 160

Registration Number: NCT02018094

Locations: 🇬🇧
Hull Royal Infirmary, Hull, United Kingdom

Administration of Subcutaneous Teicoplanin in the Treatment of Osteoarticular Infections: Tolerance Study

Phase 2

Completed

Conditions: Osteoarticular Infection

Interventions: Drug: teicoplanin

First Posted Date: 2013-03-21

Last Posted Date: 2016-08-03

Lead Sponsor: Centre Hospitalier Universitaire, Amiens

Target Recruit Count: 30

Registration Number: NCT01815541

Locations: 🇫🇷
CHU Amiens, Amiens, Picardie, France

Study of Antibiotics in Cerebrospinal Fluid Following Intravenous Injection

Phase 1

Withdrawn

Conditions: Neurosurgery

Interventions: Drug: Linezolid
Drug: Vancomycin
Drug: Teicoplanin

First Posted Date: 2009-06-19

Last Posted Date: 2015-01-26

Lead Sponsor: Aarhus University Hospital

Registration Number: NCT00925093

Teicoplanin Prophylaxis for Total Hip or Knee Arthroplasty

Phase 4

Completed

Conditions: Total Hip and Knee Arthroplasties

Interventions: Drug: β-lactams or ciprofloxacin
Drug: Teicoplanin

First Posted Date: 2008-07-21

Last Posted Date: 2008-07-21

Lead Sponsor: University of Athens

Target Recruit Count: 616

Registration Number: NCT00719056

Locations: 🇬🇷
2nd Department of Orthopedics, KAT Hospital, Maroussi, Athens, Greece
🇬🇷
3rd Department of Orthopedics, KAT Hospital, Maroussi, Athens, Greece
🇬🇷
4th Department of Orthopedics, KAT Hospital, Maroussi, Athens, Greece

Meropenem Versus Meropenem Plus Glycopeptide in Patients With Febrile Neutropenia After Allogenic Blood Stem Cell Transplantation

Completed

Conditions: Allogenic Blood Stem Cell Transplantation
Febrile Neutropenia

First Posted Date: 2007-04-19

Last Posted Date: 2009-05-12

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 392

Registration Number: NCT00462878

Locations: 🇪🇸
Hospital Universitario de Canarias, Tenerife, Canarias, Spain
🇪🇸
Hospital Central de Asturias, Oviedo, Asturias, Spain
🇪🇸
Hospital Verge de la Cinta, Tortosa, Tarragona, Spain

and more 61 locations

Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients

Phase 4

Completed

Conditions: Infection
Febrile Neutropenia

Interventions: Drug: Teicoplanin
Drug: Vancomycin

First Posted Date: 2007-03-30

Last Posted Date: 2009-03-06

Lead Sponsor: Sanofi

Target Recruit Count: 197

Registration Number: NCT00454272

Locations: 🇹🇷
Sanofi aventis administrative office, Istanbul, Turkey

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy